New modalities of cancer treatment for NSCLC: focus on immunotherapy.
New modalities of cancer treatment for NSCLC: focus on immunotherapy.
复制标题
DOI：
10.2147/cmar.s57550
复制
发表时间：
2014
影响因子：
3.3
通讯作者：
Davies M
中科院分区：
文献类型：
--
作者：
Davies M
免疫学和抗肿瘤免疫反应的最新进展导致了新的免疫疗法的发展，包括疫苗接种方法和抑制免疫检查点途径的单克隆抗体。这些策略在黑色素瘤中显示出活性，现在正在肺癌中进行测试。靶向细胞毒性T淋巴细胞相关抗原-4和程序性细胞死亡蛋白-1免疫检查点通路的抗体药物通过恢复针对癌细胞的免疫应答发挥作用，并且由于其作用机制而与非常规应答模式和免疫相关不良事件相关。随着这些新药物进入临床，护士和其他医疗保健提供者将需要了解免疫疗法的独特疗效和安全性，以优化潜在的患者获益。本文综述了肺癌免疫治疗中的新药物，以及免疫治疗患者的管理策略。
Recent advances in the understanding of immunology and antitumor immune responses have led to the development of new immunotherapies, including vaccination approaches and monoclonal antibodies that inhibit immune checkpoint pathways. These strategies have shown activity in melanoma and are now being tested in lung cancer. The antibody drugs targeting cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death protein-1 immune checkpoint pathways work by restoring immune responses against cancer cells, and are associated with unconventional response patterns and immune-related adverse events as a result of their mechanism of action. As these new agents enter the clinic, nurses and other health care providers will require an understanding of the unique efficacy and safety profiles with immunotherapy to optimize potential patient benefits. This paper provides a review of the new immunotherapeutic agents in development for lung cancer, and strategies for managing patients on immunotherapy.